Targeting the DNA damage response for patients with lymphoma : preclinical and clinical evidences
- Carrassa, Laura Tumor Cell Biology Unit, Core Research Laboratory, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy
- Colombo, Ilaria Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
- Damia, Giovanna Laboratory of Molecular Pharmacology, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
- Bertoni, Francesco Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland - Institute of Oncology Research (IOR), Faculty of Biomedical Sciences, Università della Svizzera italiana, Switzerland
-
11.08.2020
Published in:
- Cancer treatment reviews. - 2020, vol. 90, p. 11
English
The DNA damage response (DDR) is a well-coordinated cellular network activated by DNA damage. The unravelling of the key players in DDR, their specific inactivation in different tumor types and the synthesis of specific chemical inhibitors of DDR represent a new hot topic in cancer therapy. In this article, we will review the importance of DDR in lymphoma development and how this can be exploited therapeutically. Specifically, we will focus on CHK1, WEE1, ATR, DNA-PK and PARP inhibitors, for which preclinical data as single agents or in combination has been accumulating, fostering their clinical development. The few available clinical data on these inhibitors will also be discussed.
- Language
-
- English
- Classification
- Pathology, clinical medicine
- License
- CC BY-NC-ND
- Open access status
- hybrid
- Identifiers
-
- RERO DOC 333728
- DOI 10.1016/j.ctrv.2020.102090
- ARK ark:/12658/srd1319258
- Persistent URL
- https://n2t.net/ark:/12658/srd1319258
Statistics
Document views: 238
File downloads:
- Bertoni_2020_ctr.pdf: 249